Search

19/06/2024 Omicron SARS-CoV-2 infection management and outcomes in patients with hematologic disease and recipients of cell therapy
Pinana, JL, Vazquez, L, Heras, I, Aiello, TF, López-Corral, L, Arroyo, I, Soler-Espejo, E, García-Cadenas, I, Garcia-Gutierrez, V, Aroca, C, Chorao, P, Olave, MT, Lopez-Jimenez, J, Gómez, MA, Arellano, E, Cuesta-Casas, M, Avendano-Pita, A, González-Santillana, C, Hernández-Rivas, JA, Roldán-Perez, A, Mico-Cerdá, M, Guerreiro, M, Morell, J, Rodriguez-Galvez, P, Labrador, J, Campos, D, Cedillo, A, Vidal, CG, Martino, R, Solano, C. Omicron SARS-CoV-2 infection management and outcomes in patients with hematologic disease and recipients of cell therapy. Frontiers in Oncology. 2024; 14DOI:10.3389/fonc.2024.1389345. PMID:39015498. IF:3.300(Q2/4D).
01/05/2024 Guidelines for the management of Toxoplasma gondii infection and disease in patients with haematological malignancies and after haematopoietic stem-cell transplantation: guidelines from the 9th European Conference on Infections in Leukaemia, 2022.
Aerts R, Mehra V, Groll AH, Martino R, Lagrou K, Robin C, Perruccio K, Blijlevens N, Nucci M, Slavin M, Bretagne S, Cordonnier C. Guidelines for the management of Toxoplasma gondii infection and disease in patients with haematological malignancies and after haematopoietic stem-cell transplantation: guidelines from the 9th European Conference on Infections in Leukaemia, 2022.. LANCET INFECTIOUS DISEASES. 2024; 24(5)DOI:10.1016/S1473-3099(23)00495-4. PMID:38134949. IF:31.000(Q1/1D).
01/05/2024 Autologous hematopoietic cell transplantation for T-cell prolymphocytic leukemia: a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT
Drozd-Sokolowska, J, Gras, L, Koster, L, Martino, R, Salas, MQ, Salmenniemi, U, Zudaire, T, Yañez, L, Bellido, M, Collin, M, Kaufmann, M, Kozlowski, P, Poiré, X, Ferra, C, Sampol, A, Wilson, KMO, Cairoli, A, Gedde-Dahl, T, Deconinck, E, Mirabile, M, Suarez, F, Raj, K, van Gelder, M, Yakoub-Agha, I, Tournilhac, O, Mclornan, DP. Autologous hematopoietic cell transplantation for T-cell prolymphocytic leukemia: a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT. HAEMATOLOGICA. 2024; 109(5)DOI:10.3324/haematol.2023.284359. PMID:38205539. IF:10.100(Q1/2D).
01/12/2023 Impact of SCHOLAR-1 Criteria on Chimeric Antigen Receptor T Cell Therapy Efficacy in Aggressive B Lymphoma: A Real-World GELTAMO/GETH Study
Bastos-Oreiro M., Gutierrez A., Iacoboni G., López Corral L., Reguera J.L., Abrisqueta P., Delgado J., Terol M.J., Hernani R., Martínez N., Ortíz V., Bailen R., Gomez-Centurión I., Caballero A., Sanz J., Guerra Domínguez L., Luzardo H., Mussetti A., Jiménez-Ubieto A., Sancho J.M., Sureda A., Pérez A., Barba P., Kwon M., Martín García-Sancho A.. Impact of SCHOLAR-1 Criteria on Chimeric Antigen Receptor T Cell Therapy Efficacy in Aggressive B Lymphoma: A Real-World GELTAMO/GETH Study. Transplantation And Cellular Therapy. 2023; 29(12)DOI:10.1016/j.jtct.2023.08.026. PMID:37659694. IF:3.600(Q1/3D).
01/12/2023 Secreted Protein Acidic and Rich in Cysteine (SPARC) Polymorphisms in Response to Neoadjuvant Chemotherapy in HER2-Negative Breast Cancer Patients
Arqueros, C, Salazar, J, Gallardo, A, Andrés, M, Tibau, A, Bell, OL, Artigas, A, Lasa, A, Cajal, T, Lerma, E, Barnadas, A. Secreted Protein Acidic and Rich in Cysteine (SPARC) Polymorphisms in Response to Neoadjuvant Chemotherapy in HER2-Negative Breast Cancer Patients. Biomedicines. 2023; 11(12)DOI:10.3390/biomedicines11123231. PMID:38137452. IF:3.900(Q1/3D).
16/11/2023 Outcome improvement over time in reduced intensity conditioning hematopoietic transplantation: a 20-year experience
Esquirol, A, Cadenas, IG, Novelli, S, Garrido, A, Caballero, AC, Oñate, G, Lopez, J, Redondo, S, Argüello, M, Saavedra, S, Moreno, C, Briones, J, Sierra, J, Martino, R. Outcome improvement over time in reduced intensity conditioning hematopoietic transplantation: a 20-year experience. ANNALS OF HEMATOLOGY. 2023; 103(1)DOI:10.1007/s00277-023-05530-w. PMID:37971549. IF:3.000(Q2/4D).